## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-08-18_Virtual Town Hall 67_fixnames.md
last updated: 2025-01-04 Created QA Sections
link pdf: https://www.fda.gov/media/152560/download?attachment
link youtube: https://youtu.be/sPuLvzIyUkk
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Priorities for SARS-CoV-2 Test Development

QA Block 1-1
CLARIFIED QUESTION: What review pathway does the FDA recommend for an antigen test for SARS-CoV-2, either the EUA review pathway or the traditional premarket review pathway?
CLARIFIED ANSWER: The FDA recommends the EUA review pathway as the fastest and least burdensome option for antigen tests addressing public health needs, though sponsors may also pursue full marketing authorization via the de novo or 510(k) pathways.
VERBATIM QUESTION: What review pathway does the FDA recommend for an antigen test for SARS-CoV-2, either the EUA review pathway or the traditional premarket review pathway?
VERBATIM ANSWER: And, similar to what we've said on previous calls about both molecular and antigen tests, for tests that will most benefit the current public health needs, EUA does remain the fastest and least burdensome route to authorization. Sponsors interested in pursuing full marketing authorization through a de novo or a 510K are also welcomed to do so.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA review pathway, Traditional premarket review, Antigen tests
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What additional clinical performance requirements are there for traditional premarket review pathways, such as 510K or de novo, compared to an EUA request?
CLARIFIED ANSWER: FDA expects higher-powered, prospective clinical studies and analytical studies for traditional premarket review pathways compared to an EUA. Referencing the SARS-CoV-2 BioFire de novo summary provides insights into FDA expectations for full marketing authorization.
VERBATIM QUESTION: What additional clinical performance requirements are there for traditional premarket review pathways, such as 510K or de novo, compared to an EUA request?
VERBATIM ANSWER: Since we've not yet authorized an antigen SARS-CoV-2 test for full marketing yet, we would generally recommend a pre-submission. Typically, for full marketing authorization, we're likely to expect a higher-powered, prospective clinical study, so more positive than negative, than what we would expect to support an EUA, as well as analytical studies of course. And, while it is specific to molecular, the decision summary for the SARS-CoV-2 BioFire de novo, which is the only SARS-CoV-2 test that has received full marketing authorization at this time, might give some insight into FDA's thinking about what we're looking for full marketing authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA review pathways, Clinical performance requirements, Diagnostic tests
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: Are both prospective and retrospective studies required if a developer plans to use the traditional premarket review pathway for an antigen test for SARS-CoV-2?
CLARIFIED ANSWER: The FDA generally recommends a pre-submission. For full marketing authorization, they are likely to expect a higher-powered, prospective clinical study with more positives and negatives compared to an EUA.
VERBATIM QUESTION: Are both prospective and retrospective studies required if a developer plans to use the traditional premarket review pathway for an antigen test for SARS-CoV-2?
VERBATIM ANSWER: Since we've not yet authorized an antigen SARS-CoV-2 test for full marketing yet, we would generally recommend a pre-submission. Typically, for full marketing authorization, we're likely to expect a higher-powered, prospective clinical study, so more positive than negative, than what we would expect to support an EUA, as well as analytical studies of course.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Traditional premarket review, Antigen test study requirements
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What types of diagnostic tests are considered high-priority by the FDA in the current stage of the pandemic?
CLARIFIED ANSWER: The FDA prioritizes diagnostic tests that provide high-volume testing, including point-of-care tests, home diagnostic tests, central lab tests, and diagnostic home collection.
VERBATIM QUESTION: What types of diagnostic tests are considered high-priority by the FDA in the current stage of the pandemic?
VERBATIM ANSWER: We continue to prioritize access to high-volume testing nationwide, particularly for diagnostic tests, so point-of-care diagnostic tests, home diagnostic tests, high-volume central lab tests, and diagnostic home collection. So those are the priorities for, I presume, obvious reasons. And we continue those.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Diagnostic test priorities, COVID-19 high-priority tests
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: Why are prescription multianalyte tests prioritized, but not over-the-counter multianalyte tests?
CLARIFIED ANSWER: FDA prioritizes prescription multianalyte tests but not over-the-counter ones as a matter of policy.
VERBATIM QUESTION: Why are prescription multianalyte tests prioritized, but not over-the-counter multianalyte tests?
VERBATIM ANSWER: Sure. Yeah, it's part of the discussion on priorities. I know we've had a lot of questions recently about multianalyte tests. So I just wanted to clarify that we are accepting and prioritizing prescription multianalyte tests, but not over-the-counter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multianalyte test prioritization, Prescription vs. OTC diagnostics
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: Does the FDA provide written responses for case-specific questions not addressed during the town hall?
CLARIFIED ANSWER: FDA provides written responses for case-specific questions not addressed during the town hall and advises following up via email if no response is received within a few days.
VERBATIM QUESTION: Does the FDA provide written responses for case-specific questions not addressed during the town hall?
VERBATIM ANSWER: As I have mentioned on previous calls, we do sometimes receive questions that are too detailed or case specific to address on this call. For those, we do try to send a response in writing within a few days. So, if you've submitted a question and don't hear it addressed on the call today, please keep an eye out for a written response. And, if you don't receive one within a few days, please reach back out to the CDRH- EUA-Templates@fda.hhs.gov mailbox for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Written responses, Case-specific questions, FDA communication
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What steps should developers take if they do not receive a written response from the FDA within a few days after submitting a question?
CLARIFIED ANSWER: If developers do not receive a written response within a few days after submitting a question, they should contact the CDRH-EUA-Templates@fda.hhs.gov mailbox for an update.
VERBATIM QUESTION: What steps should developers take if they do not receive a written response from the FDA within a few days after submitting a question?
VERBATIM ANSWER: As I have mentioned on previous calls, we do sometimes receive questions that are too detailed or case specific to address on this call. For those, we do try to send a response in writing within a few days. So, if you've submitted a question and don't hear it addressed on the call today, please keep an eye out for a written response. And, if you don't receive one within a few days, please reach back out to the CDRH-EUA-Templates@fda.hhs.gov mailbox for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Developer communication, FDA response timeframe
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What lessons can be learned from the decision summary for the SARS-CoV-2 BioFire de novo to guide full marketing authorization submissions for other tests?
CLARIFIED ANSWER: The decision summary for the SARS-CoV-2 BioFire de novo provides insight into FDA requirements for full marketing authorization, although it applies specifically to molecular tests.
VERBATIM QUESTION: What lessons can be learned from the decision summary for the SARS-CoV-2 BioFire de novo to guide full marketing authorization submissions for other tests?
VERBATIM ANSWER: And, while it is specific to molecular, the decision summary for the SARS-CoV-2 BioFire de novo, which is the only SARS-CoV-2 test that has received full marketing authorization at this time, might give some insight into FDA's thinking about what we're looking for full marketing authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BioFire de novo decision summary, Full marketing authorization, FDA requirements
REVIEW FLAG: False


#### 2. EUA Requirements for CLIA Lab-Based Home Collection Tests

QA Block 2-1
CLARIFIED QUESTION: Are you still accepting CLIA lab-based EUA applications?
CLARIFIED ANSWER: FDA requires EUA submission for CLIA lab-based applications involving home collection. For standard lab-developed tests (LDTs) without device-related aspects, the FDA is in discussions with HHS.
VERBATIM QUESTION: Are you still accepting CLIA lab-based EUA applications?
VERBATIM ANSWER: Yeah, so home collection is considered a device. And we do require review of that. And so, if you have an LDT that wants to add home collection, then we look forward to getting the submission and working with you. If it's a standard LDT and it doesn't involve, say, home collection or some other device-related issue, we are still in discussions with HHS on LDTs.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA lab EUA applications, home collection requirements, LDT discussions
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What would be the expected turnaround or response time for CLIA lab-based EUA applications?
CLARIFIED ANSWER: FDA recommends sending detailed questions to their templates email address to receive directed feedback, and they aim to respond rapidly.
VERBATIM QUESTION: What would be the expected turnaround or response time for CLIA lab-based EUA applications?
VERBATIM ANSWER: You know, what I recommend, I can imagine some scenarios where we've given guidance in the past that complicates this answer. So I wonder, John, if you wouldn't mind sending an email to our templates email address and ask to be connected with f and Tim. And we'll find out a little bit more details and give you a little bit more directed feedback. And, if it comes to us, we'll do that rapidly, OK?
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA lab-based EUA turnaround time, FDA consultation for EUA, Response timeframe
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: For a developer creating a test performed solely in a CLIA lab at point of care, would an EUA request be required?
CLARIFIED ANSWER: FDA expects an EUA request for a test performed solely in a CLIA lab at point of care.
VERBATIM QUESTION: For a developer creating a test performed solely in a CLIA lab at point of care, would an EUA request be required?
VERBATIM ANSWER: Right, so, for that, we would expect to see an EUA request for that.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirement for CLIA lab, point-of-care testing
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: What constitutes a home collection device requiring FDA review?
CLARIFIED ANSWER: Home collection devices are considered devices that require FDA review. LDTs adding home collection would need a review submission, while standard LDTs without home collection are still under discussion with HHS.
VERBATIM QUESTION: What constitutes a home collection device requiring FDA review?
VERBATIM ANSWER: Yeah, so home collection is considered a device. And we do require review of that. And so, if you have an LDT that wants to add home collection, then we look forward to getting the submission and working with you. If it's a standard LDT and it doesn't involve, say, home collection or some other device-related issue, we are still in discussions with HHS on LDTs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home collection devices, FDA review requirements
REVIEW FLAG: False

QA Block 2-10
CLARIFIED QUESTION: Under what circumstances does an LDT need to submit an EUA for adding home collection?
CLARIFIED ANSWER: If an LDT adds home collection, it is considered a device and requires an EUA submission. Standard LDTs without home collection or device issues are under discussion with HHS.
VERBATIM QUESTION: Under what circumstances does an LDT need to submit an EUA for adding home collection?
VERBATIM ANSWER: Yeah, so home collection is considered a device. And we do require review of that. And so, if you have an LDT that wants to add home collection, then we look forward to getting the submission and working with you. If it's a standard LDT and it doesn't involve, say, home collection or some other device-related issue, we are still in discussions with HHS on LDTs.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT EUA requirements, Home collection as a device
REVIEW FLAG: False

QA Block 2-11
CLARIFIED QUESTION: Are LDTs without home collection devices still under regulatory discussion with HHS?
CLARIFIED ANSWER: LDTs developed and used solely in a single lab, without home collection, are still under regulatory discussion with HHS regarding the statement issued last summer.
VERBATIM QUESTION: Are LDTs without home collection devices still under regulatory discussion with HHS?
VERBATIM ANSWER: Yeah, if it is a-- if it is a test that is developed and used solely in a single lab-- so it's a lab-developed test that does not have home collection-- then that is something that is still under discussion with HHS regarding the statement they issued last summer about LDTs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: LDTs, regulatory discussion, home collection
REVIEW FLAG: False

QA Block 2-13
CLARIFIED QUESTION: What steps should a developer follow to clarify specific test scenarios with the FDA?
CLARIFIED ANSWER: The FDA recommends emailing their templates email address to connect with their team for further clarification and directed feedback on specific test scenarios.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: You know, what I recommend, I can imagine some scenarios where we've given guidance in the past that complicates this answer. So I wonder, John, if you wouldn't mind sending an email to our templates email address and ask to be connected with f and Tim. And we'll find out a little bit more details and give you a little bit more directed feedback. And, if it comes to us, we'll do that rapidly, OK?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA clarification, communication with FDA
REVIEW FLAG: False


#### 3. Sample Size Considerations for Antibody Test Development

QA Block 3-1
CLARIFIED QUESTION: Does the inclusion of both vaccinated and unvaccinated individuals change the sample size considerations for a total antibody test clinical trial?
CLARIFIED ANSWER: Inclusion of both vaccinated and unvaccinated individuals can pose a challenge, especially for detecting true positives due to potential overlap in post-vaccination and post-infection antibody presence. However, it is still feasible to meet sample size requirements. For negatives, pre-pandemic banked samples can be considered if challenges arise in finding true negatives.
VERBATIM QUESTION: Does the inclusion of both vaccinated and unvaccinated individuals change the sample size considerations for a total antibody test clinical trial?
VERBATIM ANSWER: So, for the positives, you know, vaccinated individuals would present a challenge for total antibody tests because the spike protein will be detected. And you won't know if you're detecting post-vaccination or post-infection. Unfortunately, there is a huge percentage of those in the US now who are not vaccinated and who are acquiring COVID infection. And so it really shouldn't be a challenge to get 30 positives. The 30 that are not vaccine-- or are vaccine naive. The negatives, as we increase the numbers of US citizens who are-- or folks in the US who are either vaccinated and/or post-infection, the latest estimates I've seen is that somewhere just shy of 10% of those in the US-- and I think numerous publications, high-quality publications, note this is somewhere shy of 10% have been infected in the US based on seroprevalence. And then, of course, somewhere around 50% of the people in the US have gotten somewhere around one vaccine at least. So that unfortunately leaves about somewhere around 40% of the folks who are both vaccine naive and potentially have not been infected. You can also use pre-pandemic banked negative samples for the negative pool. Don't know how pre-pandemic banks are doing as far as available volumes to provide to test developers, but that's certainly an option. I see that serology test developers will be having an increasing challenge to find true negative, let's say, fresh samples, during the pandemic samples. And, when you run into those sort of problems, just chat with our review staff. You know, eventually, we are likely to have to move to a different comparator method establishing, initially, probably sooner on the negative side and then, eventually, potentially on the positive side, as we unfortunately move to 100% either post- infection and/or post-vaccination population. But, for right now, we think it's still doable. The numbers are relatively small at 30 and 75.
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sample size considerations, Total antibody test, Vaccinated vs. unvaccinated participants
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Does the FDA have a recommendation on the distribution of positive and negative samples required if both vaccinated and unvaccinated individuals are included?
CLARIFIED ANSWER: FDA acknowledges challenges in recruiting vaccinated individuals for antibody tests because vaccination may affect test results. It advises using vaccine-naive individuals for positives and allows using pre-pandemic negative samples if supply issues arise. FDA advises consulting review staff in case of difficulties.
VERBATIM QUESTION: Does the FDA have a recommendation on the distribution of positive and negative samples required if both vaccinated and unvaccinated individuals are included?
VERBATIM ANSWER: For the positives, you know, vaccinated individuals would present a challenge for total antibody tests because the spike protein will be detected. And you won't know if you're detecting post-vaccination or post-infection. Unfortunately, there is a huge percentage of those in the US now who are not vaccinated and who are acquiring COVID infection. And so it really shouldn't be a challenge to get 30 positives. The 30 that are not vaccine-- or are vaccine naive. The negatives, as we increase the numbers of US citizens who are-- or folks in the US who are either vaccinated and/or post-infection, the latest estimates I've seen is that somewhere just shy of 10% of those in the US-- and I think numerous publications, high-quality publications, note this is somewhere shy of 10% have been infected in the US based on seroprevalence. And then, of course, somewhere around 50% of the people in the US have gotten somewhere around one vaccine at least. So that unfortunately leaves about somewhere around 40% of the folks who are both vaccine naive and potentially have not been infected. You can also use pre-pandemic banked negative samples for the negative pool. Don't know how pre-pandemic banks are doing as far as available volumes to provide to test developers, but that's certainly an option. I see that serology test developers will be having an increasing challenge to find true negative, let's say, fresh samples, during the pandemic samples. And, when you run into those sort of problems, just chat with our review staff. You know, eventually, we are likely to have to move to a different comparator method establishing, initially, probably sooner on the negative side and then, eventually, potentially on the positive side, as we unfortunately move to 100% either post- infection and/or post-vaccination population. But, for right now, we think it's still doable. The numbers are relatively small at 30 and 75. Hopefully, that's helpful.
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample distribution, vaccine impacts on testing, serology recruitment
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: What challenges do vaccinated individuals present when being used as positives in total antibody tests?
CLARIFIED ANSWER: Vaccinated individuals pose a challenge for total antibody tests as the spike protein will be detected, making it unclear whether the detection is due to vaccination or infection.
VERBATIM QUESTION: What challenges do vaccinated individuals present when being used as positives in total antibody tests?
VERBATIM ANSWER: So, for the positives, you know, vaccinated individuals would present a challenge for total antibody tests because the spike protein will be detected. And you won't know if you're detecting post-vaccination or post-infection.
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: challenges with vaccinated individuals, antibody tests, spike protein detection
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Can pre-pandemic banked negative samples be used to meet negative sample requirements?
CLARIFIED ANSWER: Pre-pandemic banked negative samples can be utilized to meet negative sample requirements, though availability may be limited.
VERBATIM QUESTION: Can pre-pandemic banked negative samples be used to meet negative sample requirements?
VERBATIM ANSWER: You can also use pre-pandemic banked negative samples for the negative pool. Don't know how pre-pandemic banks are doing as far as available volumes to provide to test developers, but that's certainly an option.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: negative sample requirements, pre-pandemic samples, serology testing
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What should test developers do if they face difficulties obtaining true negative samples due to vaccination and infection rates?
CLARIFIED ANSWER: FDA advises test developers to contact the FDA review staff if they face challenges obtaining true negative samples. Alternative comparator methods may need to be established as the population reaches 100% post-infection or post-vaccination.
VERBATIM QUESTION: What should test developers do if they face difficulties obtaining true negative samples due to vaccination and infection rates?
VERBATIM ANSWER: I see that serology test developers will be having an increasing challenge to find true negative, let's say, fresh samples, during the pandemic samples. And, when you run into those sort of problems, just chat with our review staff. You know, eventually, we are likely to have to move to a different comparator method establishing, initially, probably sooner on the negative side and then, eventually, potentially on the positive side, as we unfortunately move to 100% either post- infection and/or post-vaccination population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: true negative sample challenges, comparator methods, serology testing guidance
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: When would the FDA consider moving to a different comparator method for test validation?
CLARIFIED ANSWER: The FDA may consider switching to a different comparator method initially on the negative side and potentially later on the positive side as the population approaches 100% post-infection or post-vaccination.
VERBATIM QUESTION: When would the FDA consider moving to a different comparator method for test validation?
VERBATIM ANSWER: You know, eventually, we are likely to have to move to a different comparator method establishing, initially, probably sooner on the negative side and then, eventually, potentially on the positive side, as we unfortunately move to 100% either post-infection and/or post-vaccination population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test comparator method, test validation
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: Are there any guidelines on the use of seroprevalence data to estimate sample availability?
CLARIFIED ANSWER: Seroprevalence data indicates that around 10% of the US population has been infected, and about 50% has received at least one vaccine, leaving around 40% who are vaccine-naive and potentially uninfected.
VERBATIM QUESTION: Are there any guidelines on the use of seroprevalence data to estimate sample availability?
VERBATIM ANSWER: The negatives, as we increase the numbers of US citizens who are-- or folks in the US who are either vaccinated and/or post-infection, the latest estimates I've seen is that somewhere just shy of 10% of those in the US-- and I think numerous publications, high-quality publications, note this is somewhere shy of 10% have been infected in the US based on seroprevalence. And then, of course, somewhere around 50% of the people in the US have gotten somewhere around one vaccine at least. So that unfortunately leaves about somewhere around 40% of the folks who are both vaccine naive and potentially have not been infected.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: seroprevalence, sample availability, vaccine status data
REVIEW FLAG: False


#### 4. Smartphone Interpretation versus Visual for Antigen Test Validation

QA Block 4-1
CLARIFIED QUESTION: Do a certain number of positives and negatives need to come specifically from participants using paper instructions versus a smartphone app for clinical evaluation of OTC home-use antigen tests?
CLARIFIED ANSWER: The FDA confirms that 30 positives and 30 negatives must come from participants using visual interpretation and separately another 30 positives and 30 negatives using the smartphone app interpretation.
VERBATIM QUESTION: Do a certain number of positives and negatives need to come specifically from participants using paper instructions versus a smartphone app for clinical evaluation of OTC home-use antigen tests?
VERBATIM ANSWER: That is correct, yeah.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC home-use antigen test evaluation, visual vs. smartphone app interpretation
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Does interpreting a test with a smartphone app require the device to capture and analyze an image to determine results?
CLARIFIED ANSWER: The FDA considers a test to be interpreted by a smartphone app when the device's camera captures an image, performs image analysis, and determines whether the test result is positive or negative. Simply recording a visually-read result on the app does not count as interpretation by the app.
VERBATIM QUESTION: Does interpreting a test with a smartphone app require the device to capture and analyze an image to determine results?
VERBATIM ANSWER: Yeah. So, when we talk about a smartphone app interpreting the test, it's not recording. It's not having the patient record the result on the smartphone manually. It's you have a camera function. And you have a camera function, and the camera records an image. And it is image analysis, and the smartphone image analysis is deciding whether the test is positive or negative. It's when the smartphone is doing all of that that we need to see a separate 30 positive and 30 negative in the OTC environment. But, if all of the smartphone is doing is having the patient record the result that they visually read, that is part of the user testing and the clinical study. And you don't need to have a separate study to analyze that.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone app test interpretation, Clinical study requirements
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What is the difference between a smartphone app capturing and analyzing an image versus a user manually recording the result?
CLARIFIED ANSWER: A smartphone app interpreting the test involves the camera function capturing an image, followed by image analysis to automatically determine the test result. In contrast, manually entering a visually interpreted result into the app does not count as smartphone interpretation and does not require a separate study.
VERBATIM QUESTION: What is the difference between a smartphone app capturing and analyzing an image versus a user manually recording the result?
VERBATIM ANSWER: Yeah. So, when we talk about a smartphone app interpreting the test, it's not recording. It's not having the patient record the result on the smartphone manually. It's you have a camera function. And you have a camera function, and the camera records an image. And it is image analysis, and the smartphone image analysis is deciding whether the test is positive or negative. It's when the smartphone is doing all of that that we need to see a separate 30 positive and 30 negative in the OTC environment. But, if all of the smartphone is doing is having the patient record the result that they visually read, that is part of the user testing and the clinical study. And you don't need to have a separate study to analyze that.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone app interpretations, manual reporting, clinical testing requirements
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: For tests interpreted entirely by smartphone image analysis, what validation data does the FDA require?
CLARIFIED ANSWER: For smartphone image-based interpretation, the FDA requires a separate study demonstrating 30 positive and 30 negative results in an OTC environment. Manually recording visual results on a smartphone does not need a separate analysis.
VERBATIM QUESTION: For tests interpreted entirely by smartphone image analysis, what validation data does the FDA require?
VERBATIM ANSWER: Yeah. So, when we talk about a smartphone app interpreting the test, it's not recording. It's not having the patient record the result on the smartphone manually. It's you have a camera function. And you have a camera function, and the camera records an image. And it is image analysis, and the smartphone image analysis is deciding whether the test is positive or negative. It's when the smartphone is doing all of that that we need to see a separate 30 positive and 30 negative in the OTC environment. But, if all of the smartphone is doing is having the patient record the result that they visually read, that is part of the user testing and the clinical study. And you don't need to have a separate study to analyze that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone image analysis, validation data, OTC tests
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: If a smartphone app is only used to record a manually read result, does this require a separate clinical evaluation?
CLARIFIED ANSWER: If a smartphone app only records results manually read by the user, no separate clinical evaluation is needed. A separate study is required only when the app itself interprets the test result using image analysis.
VERBATIM QUESTION: If a smartphone app is only used to record a manually read result, does this require a separate clinical evaluation?
VERBATIM ANSWER: Yeah. So, when we talk about a smartphone app interpreting the test, it's not recording. It's not having the patient record the result on the smartphone manually. It's you have a camera function. And you have a camera function, and the camera records an image. And it is image analysis, and the smartphone image analysis is deciding whether the test is positive or negative. It's when the smartphone is doing all of that that we need to see a separate 30 positive and 30 negative in the OTC environment. But, if all of the smartphone is doing is having the patient record the result that they visually read, that is part of the user testing and the clinical study. And you don't need to have a separate study to analyze that.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone app interpretation, clinical evaluation, over-the-counter tests
REVIEW FLAG: False


#### 5. Home-Collected Blood Samples and Regulatory Limitations

QA Block 5-1
CLARIFIED QUESTION: What happens for a blood spot collected in the home setting and sent through the mail?
CLARIFIED ANSWER: FDA clarifies that a blood spot collected at home and sent through the mail is considered a medical device and outside the scope of an LDT.
VERBATIM QUESTION: What happens for a blood spot collected in the home setting and sent through the mail?
VERBATIM ANSWER: The short answer is no. We consider that a medical device and outside the purview of an LDT.
SPEAKER QUESTION: Tom Hayhurst
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home blood spot collection, medical devices, LDT regulations
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: If a blood spot collected in the home setting can be validated for sensitivity and specificity, can the lab director sign off on a sample collected in that way?
CLARIFIED ANSWER: No, the FDA considers a blood spot collected in the home setting to be a medical device and outside the purview of a laboratory-developed test (LDT).
VERBATIM QUESTION: If a blood spot collected in the home setting can be validated for sensitivity and specificity, can the lab director sign off on a sample collected in that way?
VERBATIM ANSWER: The short answer is no. We consider that a medical device and outside the purview of an LDT.
SPEAKER QUESTION: Tom Hayhurst
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home blood collection, medical device classification, laboratory-developed tests
REVIEW FLAG: False


#### 6. Fresh vs. Artificial Saliva for COVID Testing

QA Block 6-1
CLARIFIED QUESTION: For a saliva COVID test intended for the CLIA setting with freshly collected saliva, would it be acceptable to use artificial saliva or another commercial source of saliva where the saliva isn't fresh?
CLARIFIED ANSWER: Artificial saliva is not acceptable; fresh saliva is preferred. Frozen banked saliva might be considered if validated through fresh/frozen studies to ensure freezing does not affect the sample.
VERBATIM QUESTION: For a saliva COVID test intended for the CLIA setting with freshly collected saliva, would it be acceptable to use artificial saliva or another commercial source of saliva where the saliva isn't fresh?
VERBATIM ANSWER: Yeah, that's a really specific question. And I think it's best to work with our review staff. So artificial saliva, no, that's not going to be acceptable. We see saliva continuing to be a very challenging sample type. Some recent publications imply that the viral levels can be lower, and shedding can be for shorter periods of time. I don't know what the truth is, other than we have directly observed that there's some challenges with saliva. And that doesn't allow us to authorize that sample type. So it needs to be real. Potentially, frozen banked could be used, but, in all likelihood, we'd ask you to do a fresh/frozen study to make sure that freezing the sample neither degrades or frees up additional virus and might artificially increase the sensitivity of the test. So, potentially, it's OK, but I think that's a detailed enough question, best left to our front-line review staff to help you out. Hopefully, that's somewhat helpful to you.
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva COVID-19 testing, sample type requirements, FDA review process
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Do we have to use freshly collected saliva for determining the LoD for a saliva COVID test?
CLARIFIED ANSWER: Fresh saliva is required, as artificial saliva is not acceptable. Frozen banked saliva might be used, but fresh/frozen studies are likely necessary. Detailed questions should be directed to the FDA's review staff.
VERBATIM QUESTION: Do we have to use freshly collected saliva for determining the LoD for a saliva COVID test?
VERBATIM ANSWER: Yeah, that's a really specific question. And I think it's best to work with our review staff. So artificial saliva, no, that's not going to be acceptable. We see saliva continuing to be a very challenging sample type. Some recent publications imply that the viral levels can be lower, and shedding can be for shorter periods of time. I don't know what the truth is, other than we have directly observed that there's some challenges with saliva. And that doesn't allow us to authorize that sample type. So it needs to be real. Potentially, frozen banked could be used, but, in all likelihood, we'd ask you to do a fresh/frozen study to make sure that freezing the sample neither degrades or frees up additional virus and might artificially increase the sensitivity of the test. So, potentially, it's OK, but I think that's a detailed enough question, best left to our front-line review staff to help you out. Hopefully, that's somewhat helpful to you.
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva COVID test LoD, fresh vs frozen saliva, artificial saliva
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Can I send an email to ask a specific question regarding use of artificial or frozen samples?
CLARIFIED ANSWER: Yes, you can send an email with your specific question. It might be helpful to include assay details, ideally in the context of a pre-EUA submission.
VERBATIM QUESTION: Can I send an email to ask a specific question regarding use of artificial or frozen samples?
VERBATIM ANSWER: Yes. They may want to know more about your assay. And it may be best to be in the context of a pre-EUA. And, therefore, you can just frame the topic as saying, this is what you would like to do. This is our test. And, yes/no, is this acceptable?
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: email inquiries, pre-EUA submission, sample type clarification
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What are the challenges in using saliva as a sample type in COVID-19 diagnostics?
CLARIFIED ANSWER: Saliva poses challenges as a sample type due to potentially lower viral levels and shorter viral shedding durations, which complicates reliable testing and authorization.
VERBATIM QUESTION: What are the challenges in using saliva as a sample type in COVID-19 diagnostics?
VERBATIM ANSWER: We see saliva continuing to be a very challenging sample type. Some recent publications imply that the viral levels can be lower, and shedding can be for shorter periods of time. I don't know what the truth is, other than we have directly observed that there's some challenges with saliva. And that doesn't allow us to authorize that sample type.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva as sample type, COVID-19 test validation
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Are fresh/frozen sample comparison studies required when using frozen banked saliva for validation?
CLARIFIED ANSWER: FDA would likely require a fresh/frozen comparison study for validation to confirm freezing does not degrade samples or increase test sensitivity artificially.
VERBATIM QUESTION: Are fresh/frozen sample comparison studies required when using frozen banked saliva for validation?
VERBATIM ANSWER: Potentially, frozen banked could be used, but, in all likelihood, we'd ask you to do a fresh/frozen study to make sure that freezing the sample neither degrades or frees up additional virus and might artificially increase the sensitivity of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: frozen saliva validation, fresh/frozen comparison studies, sample stability
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: How should developers frame their questions about assay validation when contacting the FDA review staff?
CLARIFIED ANSWER: Developers should describe their test and the proposed actions and frame their questions clearly, preferably in the context of a pre-EUA submission.
VERBATIM QUESTION: How should developers frame their questions about assay validation when contacting the FDA review staff?
VERBATIM ANSWER: Yes. They may want to know more about your assay. And it may be best to be in the context of a pre-EUA. And, therefore, you can just frame the topic as saying, this is what you would like to do. This is our test. And, yes/no, is this acceptable?
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: assay validation, FDA communication, pre-EUA submission
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Is it necessary to submit questions about saliva sample validation in the context of a pre-EUA submission?
CLARIFIED ANSWER: Yes, it is advisable to frame questions about saliva sample validation in the context of a pre-EUA submission, providing details about the test and specific concerns.
VERBATIM QUESTION: Is it necessary to submit questions about saliva sample validation in the context of a pre-EUA submission?
VERBATIM ANSWER: Yes. They may want to know more about your assay. And it may be best to be in the context of a pre-EUA. And, therefore, you can just frame the topic as saying, this is what you would like to do. This is our test. And, yes/no, is this acceptable?
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample validation, pre-EUA submission
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: When could freezing a saliva sample artificially increase test sensitivity?
CLARIFIED ANSWER: Freezing a saliva sample could artificially increase test sensitivity if it frees up additional virus during the process, which is why a fresh/frozen study would be requested.
VERBATIM QUESTION: When could freezing a saliva sample artificially increase test sensitivity?
VERBATIM ANSWER: Potentially, frozen banked could be used, but, in all likelihood, we'd ask you to do a fresh/frozen study to make sure that freezing the sample neither degrades or frees up additional virus and might artificially increase the sensitivity of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample freezing, Test sensitivity, Fresh/frozen study
REVIEW FLAG: False


#### 7. Impact of App Updates on FDA Review Process

QA Block 7-1
CLARIFIED QUESTION: If we update our mobile app to help school reopening, how much will it slow down our EUA review process?
CLARIFIED ANSWER: The impact on the EUA review process depends on the changes made to the app. If the changes affect the performance of reading antigen test results, the FDA may need to restart the review of clinical and analytical studies. For a quicker response, provide details about the changes and their potential impact via email to the templates address.
VERBATIM QUESTION: If we update our mobile app to help school reopening, how much will it slow down our EUA review process?
VERBATIM ANSWER: It depends. It depends on the change. If the change affects the performance of the app reading of the antigen test result, then we may have to restart our review on the clinical and analytical studies. So, if you send an email to the templates email address box and ask for Toby and Tim, they'll forward it to us, and we'll check in on your application and provide you a little bit more direct feedback on the situation. In the email, if you can say what the changes are to your app and what the potential impact is on test results, then that will help us more quickly get you a response.
SPEAKER QUESTION: Jack Feng
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review process, Mobile app updates, Impact on antigen test result performance
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: How does the FDA determine whether an app change will require restarting the review process?
CLARIFIED ANSWER: The FDA assesses whether a change impacts app performance in reading antigen test results. If affected, a new review of clinical and analytical studies may be necessary.
VERBATIM QUESTION: How does the FDA determine whether an app change will require restarting the review process?
VERBATIM ANSWER: It depends. It depends on the change. If the change affects the performance of the app reading of the antigen test result, then we may have to restart our review on the clinical and analytical studies. So, if you send an email to the templates email address box and ask for Toby and Tim, they'll forward it to us, and we'll check in on your application and provide you a little bit more--
SPEAKER QUESTION: Jack Feng
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: app changes, review process, FDA decision factors
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What details about the changes to a mobile app should developers include when contacting the FDA for feedback?
CLARIFIED ANSWER: Developers should include details about the changes to their app and the potential impact on test results when contacting the FDA for feedback.
VERBATIM QUESTION: What details about the changes to a mobile app should developers include when contacting the FDA for feedback?
VERBATIM ANSWER: In the email, if you can say what the changes are to your app and what the potential impact is on test results, then that will help us more quickly get you a response.
SPEAKER QUESTION: Jack Feng
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mobile app changes, developer communication with FDA, FDA feedback process
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Is there a specific point of contact or address to submit queries regarding updates to mobile applications tied to COVID-19 diagnostic tests?
CLARIFIED ANSWER: To submit queries regarding updates to mobile applications tied to COVID-19 diagnostic tests, send an email to the templates email address and include details about the changes and their impact on test results. This will facilitate a quicker response from the FDA.
VERBATIM QUESTION: Is there a specific point of contact or address to submit queries regarding updates to mobile applications tied to COVID-19 diagnostic tests?
VERBATIM ANSWER: If you send an email to the templates email address box and ask for Toby and Tim, they'll forward it to us, and we'll check in on your application and provide you a little bit more-- In the email, if you can say what the changes are to your app and what the potential impact is on test results, then that will help us more quickly get you a response.
SPEAKER QUESTION: Jack Feng
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission process, mobile app updates, COVID-19 diagnostics
REVIEW FLAG: False


#### 8. Home Collection Kits and EUA Requirements

QA Block 8-1
CLARIFIED QUESTION: Would a home collection kit for a nasal swab specimen qualify as part of the LDT, which is a PCR test, or would it require an EUA?
CLARIFIED ANSWER: A home collection kit for a nasal swab specimen would require an EUA unless it is already FDA authorized or used within conditions of its authorized use, as such kits are considered devices and subject to FDA review.
VERBATIM QUESTION: Would a home collection kit for a nasal swab specimen qualify as part of the LDT, which is a PCR test, or would it require an EUA?
VERBATIM ANSWER: Yes, it requires an EUA. Typically, all home collections, for something that hasn't already been FDA authorized for that specific purpose or hasn't already received an EUA for that specific purpose and you're just using it within all the conditions of the use of that home collection device, we're going to want you to come in and explain what you're doing. But, by and large, the vast majority, if not all of these, are considered devices and subject to FDA review.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home collection kits, EUA requirement, Lab-developed tests
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: What are the FDA's expectations for explaining the intended use of unauthorized home collection devices?
CLARIFIED ANSWER: The FDA expects submission for review of unauthorized home collection devices to explain their intended purpose and usage, as they are generally considered devices requiring FDA oversight.
VERBATIM QUESTION: What are the FDA's expectations for explaining the intended use of unauthorized home collection devices?
VERBATIM ANSWER: Typically, all home collections, for something that hasn't already been FDA authorized for that specific purpose or hasn't already received an EUA for that specific purpose and you're just using it within all the conditions of the use of that home collection device, we're going to want you to come in and explain what you're doing. But, by and large, the vast majority, if not all of these, are considered devices and subject to FDA review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA expectations, home collection devices, regulatory review
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Are there any specific conditions under which home collection devices might bypass the EUA process?
CLARIFIED ANSWER: Home collection devices generally require an EUA unless they have already been authorized by the FDA for specific use or conditions of use. Most such devices are considered subject to FDA review.
VERBATIM QUESTION: Are there any specific conditions under which home collection devices might bypass the EUA process?
VERBATIM ANSWER: Yes, it requires an EUA. Typically, all home collections, for something that hasn't already been FDA authorized for that specific purpose or hasn't already received an EUA for that specific purpose and you're just using it within all the conditions of the use of that home collection device, we're going to want you to come in and explain what you're doing. But, by and large, the vast majority, if not all of these, are considered devices and subject to FDA review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection devices, EUA requirements, FDA review
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Does the FDA classify all home collection kits as devices subject to review, even if they are not commercially sold?
CLARIFIED ANSWER: The FDA considers the vast majority, if not all, home collection kits as devices requiring review, even if they are not commercially sold. They typically require an EUA if not already authorized for a specific purpose.
VERBATIM QUESTION: Does the FDA classify all home collection kits as devices subject to review, even if they are not commercially sold?
VERBATIM ANSWER: Yes, it requires an EUA. Typically, all home collections, for something that hasn't already been FDA authorized for that specific purpose or hasn't already received an EUA for that specific purpose and you're just using it within all the conditions of the use of that home collection device, we're going to want you to come in and explain what you're doing. But, by and large, the vast majority, if not all of these, are considered devices and subject to FDA review.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA classification, Home collection kits, EUA requirements
REVIEW FLAG: False


#### 9. Evolving Standards for Immunity Assessment and Antibody Testing Challenges

QA Block 9-1
CLARIFIED QUESTION: What is the FDA's view on the importance and priority of antibody testing and immunity assessment in light of recent CDC data on vaccine efficacy?
CLARIFIED ANSWER: The FDA is monitoring clinical trials on immunity determination but emphasizes caution in relying on serology tests due to challenges in defining precise immunity levels for SARS-CoV-2, given mutations and variability. Progress depends on conclusive data and alignment with international standards.
VERBATIM QUESTION: What is the FDA's view on the importance and priority of antibody testing and immunity assessment in light of recent CDC data on vaccine efficacy?
VERBATIM ANSWER: Yeah, so there's more than a dozen ongoing clinical trials of immunity determination, all on ClinicalTrials.gov, that we're monitoring. The FDA is not running them. And we're looking forward to seeing the results of that before we look to offer pathways to seek- - clear pathways to seek immunity or protection claims for serology tests. If we look at other situations where the FDA has authorized serology tests for this sort of purpose, rubella is a really good example. There is a fully quantitative rubella serology tests traceable to international standard so that all the tests are in agreement when you get IUs per mL. And all the longitudinal studies have helped us understand-- helped all of us understand what a sterilizing level of antibodies are for rubella. So you know precise cutoffs above and below which you make clinical decisions about. That was the hope for SARS-CoV-2. And we are still looking forward to seeing the results of those outcomes studies. And, if they're able to define such a level that can be traceable to an international standard, in all likelihood, a fully quantitative test may be needed. Then we will move forward. And, any device that's already authorized and can meet that standard, we will update-- very willing to update their authorization without them, those developers, having to do their own outcome studies. We will not-- because we can link-- if we can link things to an international standard, then it takes away the need for all the separate serology devices that may be able to meet the need to have to do their own outcome studies. That would be very-- that would not be in the best interests of public health. However, I do want to caution listeners that we don't do serology testing for some viruses, for example, for flu. And there is a reason for that. And, due to the variants, which occasionally now appear to have breakthrough infections, even in fully vaccinated people, like Delta, it's quite clear that, when you take into account variants and mutations, that there are differing levels of-- when you measure neutralizing ability, different levels, whether you got vaccinated, or you have natural infection and what variant you got natural infection from. And then, when you look at other variants, what is the neutralizing level of antibody? And they're not-- the current data, my read of the current data-- and it's just my read-- but our team of serology experts at the FDA has been examining this and keeping track of this. So we're seeing concerning signs that it may be challenging to define a precise and accurate level of immunity or protection that would cover potentially all scenarios, whatever you were infected with or whatever you were vaccinated with and then all the current circulating mutations and vaccines. So I'm just urging caution here. We will be driven by the results of data. And, if the data supports it, the FDA will absolutely support those claims in the manner that I addressed.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antibody testing, vaccine immunity, FDA guidance
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Does the eight-month booster recommendation apply uniformly across individuals, and could serology tests help determine personal immunity status?
CLARIFIED ANSWER: The eight-month booster recommendation is likely moving toward a universal public health level guidance similar to annual flu vaccines. Currently, FDA does not recommend using serology tests to determine individual immunity as the data is complex, and valid clinical interpretations for individuals are still being studied.
VERBATIM QUESTION: Does the eight-month booster recommendation apply uniformly across individuals, and could serology tests help determine personal immunity status?
VERBATIM ANSWER: Yeah, as I said on our recent national call with infectious disease docs and clinicians, you know, I think we're looking at not who shouldn't get vaccinated, but rather who should be vaccinated and/or get a booster. The feeling that I'm getting-- and this is a feeling, and it's a gestalt of all the literature I'm reading-- is that we're moving towards a recommendation at the public health level, and it's not my decision, but more like flu, which you're supposed to get an annual flu vaccine. But, again, I'm not speaking for the FDA or the vaccine group here. I'm addressing the question of the utility and clinical validity of using serology tests here. And I will say that the benefit/risk for serology testing, as just sort of espoused by you and others that I've talked to, we don't want serology tests to be misused. And we don't want the wrong interpretations to be made on the basis of a serology test because, as I said, it's very complex. How did you gain an antibody response specifically? And have we done all of the work to find what it means for you down to the individual? I mean, population studies are one thing. And getting a p-value of less than 0.05 is one thing. But knowing what to give you as a patient, a specific recommendation, that's really what the FDA is focused on, not on population studies. We look at what is the best way to inform individual patients of their health. So to be honest, it's very complex. And we're very open to it. And I'm giving you my personal, not FDA, speak here on vaccines. And I don't want to confuse that. I really want to make sure that's in the transcript. That's just kind of the way we're looking at it. And, when I'm reading what others are recommending, I think that's what they're saying, but, again, and that's why they're making this recommendation probably for eight months to get boosters after your first vaccination.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Booster recommendation, Serology testing, Immunity interpretation
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What criteria will the FDA use to define a fully quantitative COVID-19 serology test?
CLARIFIED ANSWER: The FDA aims to define a fully quantitative COVID-19 serology test based on international standards and clear cutoffs for clinical decisions, similar to rubella serology tests. This requires outcome studies to determine precise antibody levels.
VERBATIM QUESTION: What criteria will the FDA use to define a fully quantitative COVID-19 serology test?
VERBATIM ANSWER: If we look at other situations where the FDA has authorized serology tests for this sort of purpose, rubella is a really good example. There is a fully quantitative rubella serology tests traceable to international standard so that all the tests are in agreement when you get IUs per mL. And all the longitudinal studies have helped us understand-- helped all of us understand what a sterilizing level of antibodies are for rubella. So you know precise cutoffs above and below which you make clinical decisions about. That was the hope for SARS-CoV-2. And we are still looking forward to seeing the results of those outcomes studies. And, if they're able to define such a level that can be traceable to an international standard, in all likelihood, a fully quantitative test may be needed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Quantitative serology tests, COVID-19 diagnostics, FDA criteria
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Are there plans to establish an international standard for SARS-CoV-2 antibody levels similar to rubella?
CLARIFIED ANSWER: FDA is open to establishing an international standard for SARS-CoV-2 antibody levels similar to rubella if outcome studies can define such levels traceable to a standard. Fully quantitative tests may be needed, and existing authorized devices that meet the standard may be updated without requiring separate outcome studies.
VERBATIM QUESTION: Are there plans to establish an international standard for SARS-CoV-2 antibody levels similar to rubella?
VERBATIM ANSWER: If we look at other situations where the FDA has authorized serology tests for this sort of purpose, rubella is a really good example. There is a fully quantitative rubella serology tests traceable to international standard so that all the tests are in agreement when you get IUs per mL. And all the longitudinal studies have helped us understand-- helped all of us understand what a sterilizing level of antibodies are for rubella. So you know precise cutoffs above and below which you make clinical decisions about. That was the hope for SARS-CoV-2. And we are still looking forward to seeing the results of those outcomes studies. And, if they're able to define such a level that can be traceable to an international standard, in all likelihood, a fully quantitative test may be needed. Then we will move forward. And, any device that's already authorized and can meet that standard, we will update-- very willing to update their authorization without them, those developers, having to do their own outcome studies. We will not-- because we can link-- if we can link things to an international standard, then it takes away the need for all the separate serology devices that may be able to meet the need to have to do their own outcome studies. That would be very-- that would not be in the best interests of public health.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: International standards, SARS-CoV-2 antibody levels, Rubella comparison
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: If an existing authorized serology test meets a future international standard, will the FDA update its authorization automatically without requiring new outcome studies?
CLARIFIED ANSWER: The FDA is willing to update the authorization of already authorized serology tests that meet future international standards without requiring developers to conduct new outcome studies, provided the tests can be linked to those standards.
VERBATIM QUESTION: If an existing authorized serology test meets a future international standard, will the FDA update its authorization automatically without requiring new outcome studies?
VERBATIM ANSWER: And, any device that's already authorized and can meet that standard, we will update-- very willing to update their authorization without them, those developers, having to do their own outcome studies. We will not-- because we can link-- if we can link things to an international standard, then it takes away the need for all the separate serology devices that may be able to meet the need to have to do their own outcome studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test authorization, international standards, outcome studies
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: How does the presence of COVID-19 variants like Delta impact the ability to define universal immunity thresholds through serology testing?
CLARIFIED ANSWER: The FDA highlights the challenge posed by COVID-19 variants, like Delta, in defining universal immunity thresholds through serology tests. Variants affect neutralizing antibody levels depending on infection or vaccination history, making it difficult to establish a precise threshold covering all scenarios.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: However, I do want to caution listeners that we don't do serology testing for some viruses, for example, for flu. And there is a reason for that. And, due to the variants, which occasionally now appear to have breakthrough infections, even in fully vaccinated people, like Delta, it's quite clear that, when you take into account variants and mutations, that there are differing levels of-- when you measure neutralizing ability, different levels, whether you got vaccinated, or you have natural infection and what variant you got natural infection from. And then, when you look at other variants, what is the neutralizing level of antibody? And they're not-- the current data, my read of the current data-- and it's just my read-- but our team of serology experts at the FDA has been examining this and keeping track of this. So we're seeing concerning signs that it may be challenging to define a precise and accurate level of immunity or protection that would cover potentially all scenarios, whatever you were infected with or whatever you were vaccinated with and then all the current circulating mutations and vaccines. So I'm just urging caution here. We will be driven by the results of data. And, if the data supports it, the FDA will absolutely support those claims in the manner that I addressed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 variants impact, Serology testing, Immunity thresholds
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Would population-level serology studies using p-values be insufficient for creating clinical recommendations tailored to individual patients?
CLARIFIED ANSWER: Population-level serology studies using p-values are insufficient for creating tailored clinical recommendations for individuals, as they lack the specificity needed to inform individual patient health.
VERBATIM QUESTION: Would population-level serology studies using p-values be insufficient for creating clinical recommendations tailored to individual patients?
VERBATIM ANSWER: And I will say that the benefit/risk for serology testing, as just sort of espoused by you and others that I've talked to, we don't want serology tests to be misused. And we don't want the wrong interpretations to be made on the basis of a serology test because, as I said, it's very complex. How did you gain an antibody response specifically? And have we done all of the work to find what it means for you down to the individual? I mean, population studies are one thing. And getting a p-value of less than 0.05 is one thing. But knowing what to give you as a patient, a specific recommendation, that's really what the FDA is focused on, not on population studies. We look at what is the best way to inform individual patients of their health. So to be honest, it's very complex.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing, Clinical recommendations, Population studies
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: What safeguards are in place to prevent the misuse of serology tests in making personalized clinical decisions?
CLARIFIED ANSWER: The FDA aims to prevent the misuse of serology tests by ensuring proper interpretation, focusing more on individualized health insights rather than general population studies.
VERBATIM QUESTION: What safeguards are in place to prevent the misuse of serology tests in making personalized clinical decisions?
VERBATIM ANSWER: We don't want serology tests to be misused. And we don't want the wrong interpretations to be made on the basis of a serology test because, as I said, it's very complex. How did you gain an antibody response specifically? And have we done all of the work to find what it means for you down to the individual? I mean, population studies are one thing. And getting a p-value of less than 0.05 is one thing. But knowing what to give you as a patient, a specific recommendation, that's really what the FDA is focused on, not on population studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test misuse, Clinical decision-making, FDA safeguards
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: Under what specific circumstances might the FDA consider supporting immunity claims for serology tests?
CLARIFIED ANSWER: The FDA may support immunity claims for serology tests if outcome studies define a level of immunity traceable to an international standard. This framework would remove the need for separate studies by individual test developers.
VERBATIM QUESTION: Under what specific circumstances might the FDA consider supporting immunity claims for serology tests?
VERBATIM ANSWER: Yeah, so there's more than a dozen ongoing clinical trials of immunity determination, all on ClinicalTrials.gov, that we're monitoring. The FDA is not running them. And we're looking forward to seeing the results of that before we look to offer pathways to seek- - clear pathways to seek immunity or protection claims for serology tests. If we look at other situations where the FDA has authorized serology tests for this sort of purpose, rubella is a really good example. There is a fully quantitative rubella serology tests traceable to international standard so that all the tests are in agreement when you get IUs per mL. And all the longitudinal studies have helped us understand-- helped all of us understand what a sterilizing level of antibodies are for rubella. So you know precise cutoffs above and below which you make clinical decisions about. That was the hope for SARS-CoV-2. And we are still looking forward to seeing the results of those outcomes studies. And, if they're able to define such a level that can be traceable to an international standard, in all likelihood, a fully quantitative test may be needed. Then we will move forward. And, any device that's already authorized and can meet that standard, we will update-- very willing to update their authorization without them, those developers, having to do their own outcome studies. We will not-- because we can link-- if we can link things to an international standard, then it takes away the need for all the separate serology devices that may be able to meet the need to have to do their own outcome studies. That would be very-- that would not be in the best interests of public health.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, immunity claims, FDA standards
REVIEW FLAG: False

QA Block 9-10
CLARIFIED QUESTION: How does the complexity of interpreting antibody responses influence FDA guidelines or recommendations for serology use?
CLARIFIED ANSWER: The complexity of interpreting antibody response impacts FDA recommendations for serology use, as it involves challenges in relating antibody levels to individual immunity, especially with various mutations and vaccine responses. The FDA's focus is on individual patient guidance rather than population-level studies.
VERBATIM QUESTION: How does the complexity of interpreting antibody responses influence FDA guidelines or recommendations for serology use?
VERBATIM ANSWER: Yeah, as I said on our recent national call with infectious disease docs and clinicians, you know, I think we're looking at not who shouldn't get vaccinated, but rather who should be vaccinated and/or get a booster. The feeling that I'm getting-- and this is a feeling, and it's a gestalt of all the literature I'm reading-- is that we're moving towards a recommendation at the public health level, and it's not my decision, but more like flu, which you're supposed to get an annual flu vaccine. But, again, I'm not speaking for the FDA or the vaccine group here. I'm addressing the question of the utility and clinical validity of using serology tests here. And I will say that the benefit/risk for serology testing, as just sort of espoused by you and others that I've talked to, we don't want serology tests to be misused. And we don't want the wrong interpretations to be made on the basis of a serology test because, as I said, it's very complex. How did you gain an antibody response specifically? And have we done all of the work to find what it means for you down to the individual? I mean, population studies are one thing. And getting a p-value of less than 0.05 is one thing. But knowing what to give you as a patient, a specific recommendation, that's really what the FDA is focused on, not on population studies. We look at what is the best way to inform individual patients of their health. So to be honest, it's very complex. And we're very open to it. And I'm giving you my personal, not FDA, speak here on vaccines. And I don't want to confuse that. I really want to make sure that's in the transcript.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test complexity, FDA guidelines, immunity assessment
REVIEW FLAG: False


#### 10. RT-PCR Comparators in Serology Clinical Testing Explained

QA Block 10-1
CLARIFIED QUESTION: Would you be utilizing the RT-PCR to screen and enroll for the serology clinical testing people who are positive at their initial visit?
CLARIFIED ANSWER: The FDA uses RT-PCR to determine whether a patient was infected with SARS-CoV-2 and evaluate serology test performance by days after the infection. They aim for high sensitivity within two to three weeks after infection while maintaining specificity.
VERBATIM QUESTION: Would you be utilizing the RT-PCR to screen and enroll for the serology clinical testing people who are positive at their initial visit?
VERBATIM ANSWER: So we want the RT-PCR test to establish the closest thing to truth about whether that patient was infected or not with SARS-CoV-2. And then we're looking at the day after symptoms and/or after the molecular test to look at how soon is the test, the serology test, able to detect an antibody response to that infection. And then we list performance, as you've seen in all the prior authorizations, by days after ranges. And we really want to see that, in the two to three week range, performance achieves expectations as far as sensitivity and while maintaining adequate specificity. Hopefully, that addressed your question.
SPEAKER QUESTION: D. Brinza
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RT-PCR diagnostics, Serology test evaluation, SARS-CoV-2 infection screening
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: When conducting serology testing, would you have patients undergo nasal samplings at day 7, day 14, or day 15 after their initial test if they do a follow-on visit?
CLARIFIED ANSWER: The FDA recommends using the RT-PCR test to determine infection status and suggests tracking serology test performance in the two-to-three-week range post-infection to ensure sensitivity and specificity.
VERBATIM QUESTION: When conducting serology testing, would you have patients undergo nasal samplings at day 7, day 14, or day 15 after their initial test if they do a follow-on visit?
VERBATIM ANSWER: So we want the RT-PCR test to establish the closest thing to truth about whether that patient was infected or not with SARS-CoV-2. And then we're looking at the day after symptoms and/or after the molecular test to look at how soon is the test, the serology test, able to detect an antibody response to that infection. And then we list performance, as you've seen in all the prior authorizations, by days after ranges. And we really want to see that, in the two to three week range, performance achieves expectations as far as sensitivity and while maintaining adequate specificity. Hopefully, that addressed your question.
SPEAKER QUESTION: D. Brinza
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology testing, RT-PCR comparator, test performance timing
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Are you asking patients to do both a blood test and a nasal swab for serology clinical testing?
CLARIFIED ANSWER: FDA requires RT-PCR testing to confirm SARS-CoV-2 infection and monitor antibody response timelines for serology tests, focusing on performance within 23 weeks after infection.
VERBATIM QUESTION: Are you asking patients to do both a blood test and a nasal swab for serology clinical testing?
VERBATIM ANSWER: So we want the RT-PCR test to establish the closest thing to truth about whether that patient was infected or not with SARS-CoV-2. And then we're looking at the day after symptoms and/or after the molecular test to look at how soon is the test, the serology test, able to detect an antibody response to that infection. And then we list performance, as you've seen in all the prior authorizations, by days after ranges. And we really want to see that, in the two to three week range, performance achieves expectations as far as sensitivity and while maintaining adequate specificity. Hopefully, that addressed your question.
SPEAKER QUESTION: D. Brinza
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology clinical testing, RT-PCR comparator, test performance timelines
REVIEW FLAG: False


#### 11. Guidance on Selecting Comparator for Multianalyte Tests

QA Block 11-1
CLARIFIED QUESTION: Does the FDA have any general limitations, considerations, or recommendations on selecting a cleared flu method to serve as a comparator for a multianalyte antigen test?
CLARIFIED ANSWER: For viruses other than SARS-CoV-2, previously cleared or authorized flu and other virus tests are fine as comparators, with no additional FDA recommendations.
VERBATIM QUESTION: Does the FDA have any general limitations, considerations, or recommendations on selecting a cleared flu method to serve as a comparator for a multianalyte antigen test?
VERBATIM ANSWER: If it's for viruses other than SARS-CoV-2, previously cleared or granted flu and other virus tests are fine for the comparator. We do not make any additional recommendations for that.
SPEAKER QUESTION: Jeanna MacLeod
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator flu methods, Multianalyte antigen tests, FDA recommendations
REVIEW FLAG: False


#### 12. EUA Updates for Non-Impactful App Changes

QA Block 12-2
CLARIFIED QUESTION: Is it necessary to update the EUA for app changes that do not involve the operation and use of the kit and do not affect safety and effectiveness?
CLARIFIED ANSWER: If the changes do not affect the test's performance, sensitivity, specificity, or usability, the FDA is unlikely to require data, but this should be discussed with the FDA review staff during the initial review process for clarification.
VERBATIM QUESTION: Is it necessary to update the EUA for app changes that do not involve the operation and use of the kit and do not affect safety and effectiveness?
VERBATIM ANSWER: Yeah, so, if it doesn't affect the performance, the sensitivity, specificity, usability of the test, then we're unlikely to ask for any data. But I would bring that up in the initial review process of your test and address that question with our front-line review staff. And they can give you a more detailed response on when they would like to see an amendment or supplement and when they don't need to see it or when they just want to get a notification or something, OK?
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA update requirements, app modifications, FDA review process
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What factors determine whether the FDA requires additional data for app updates that impact test performance, sensitivity, specificity, or usability?
CLARIFIED ANSWER: The FDA generally does not require additional data for app updates if they do not impact test performance, sensitivity, specificity, or usability. Questions on this should be raised during the initial review process for specific guidance.
VERBATIM QUESTION: What factors determine whether the FDA requires additional data for app updates that impact test performance, sensitivity, specificity, or usability?
VERBATIM ANSWER: Yeah, so, if it doesn't affect the performance, the sensitivity, specificity, usability of the test, then we're unlikely to ask for any data. But I would bring that up in the initial review process of your test and address that question with our front-line review staff. And they can give you a more detailed response on when they would like to see an amendment or supplement and when they don't need to see it or when they just want to get a notification or something, OK?
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA app updates, FDA additional data requirements, Test performance factors
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: Can test developers address the need for EUA amendments or notifications during the initial review process?
CLARIFIED ANSWER: Developers should raise questions about EUA amendments or notifications during the initial test review process, as the FDA's review staff can provide guidance on when amendments, supplements, or notifications are needed.
VERBATIM QUESTION: Can test developers address the need for EUA amendments or notifications during the initial review process?
VERBATIM ANSWER: Yeah, so, if it doesn't affect the performance, the sensitivity, specificity, usability of the test, then we're unlikely to ask for any data. But I would bring that up in the initial review process of your test and address that question with our front-line review staff. And they can give you a more detailed response on when they would like to see an amendment or supplement and when they don't need to see it or when they just want to get a notification or something, OK?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA amendments, FDA review process
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Are there defined guidelines for when the FDA requires notifications, amendments, or supplements for app updates?
CLARIFIED ANSWER: The FDA reviews app changes on a case-by-case basis. If updates do not affect test performance, sensitivity, specificity, or usability, data is unlikely to be required. This should be discussed during the initial review process with FDA staff to determine whether amendments, supplements, or notifications are necessary.
VERBATIM QUESTION: Are there defined guidelines for when the FDA requires notifications, amendments, or supplements for app updates?
VERBATIM ANSWER: Yeah, so, if it doesn't affect the performance, the sensitivity, specificity, usability of the test, then we're unlikely to ask for any data. But I would bring that up in the initial review process of your test and address that question with our front-line review staff. And they can give you a more detailed response on when they would like to see an amendment or supplement and when they don't need to see it or when they just want to get a notification or something, OK?
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA notification for app updates, EUA processes, Guidelines for amendments
REVIEW FLAG: False


#### 13. FDA's Role in Serial Testing and Long COVID

QA Block 13-1
CLARIFIED QUESTION: How is the FDA policing the serial testing to prevent people from misinterpreting usage instructions and reporting positives incorrectly?
CLARIFIED ANSWER: The FDA does not have resources to ensure home users perform serial testing as labeled. The agency relies on proper labeling and recognizes risks associated with OTC use without clinician involvement. OTC authorizations are assessed cautiously, considering benefits and risks.
VERBATIM QUESTION: How is the FDA policing the serial testing to prevent people from misinterpreting usage instructions and reporting positives incorrectly?
VERBATIM ANSWER: So, unfortunately or maybe fortunately, we don't have the resources to check that home OTC users are doing serial testing. That's how the devices are labeled, and that's how we want them to test. But there's really-- we don't expect the manufacturers to ensure that their users are following that. What we expect is that the labeling is good, instructs them on what to do, and then we understand that, when things go to an OTC environment, that they could be used in all sorts of different ways. And that is a risk of OTC when a clinician is not involved. And it's why really the FDA is a lot more cautious in authorizing OTCs. Now, obviously, we've done it numerous times, but those are the-- when we do our likely benefit to likely risk calculations for every EUA, for OTC, that goes into the hopper. And we compute that at least with brain power.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: policing serial testing, OTC diagnostics risks
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: Is the FDA assisting clinicians in diagnosing or monitoring post-COVID syndrome cases?
CLARIFIED ANSWER: The FDA recognizes some post-COVID cases lack prior diagnostic confirmation and relies on existing biomarkers and serology tests to support clinicians in evaluating potential long-COVID cases. The FDA is open to reviewing new diagnostic technologies but cannot provide standardized recommendations due to the diversity in approaches.
VERBATIM QUESTION: Is the FDA assisting clinicians in diagnosing or monitoring post-COVID syndrome cases?
VERBATIM ANSWER: So we know that at least some of these cases did not have an original documented diagnostic test confirmation of COVID with, say, an antigen test or an RT-PCR test. And so clinicians are seeing symptoms of an overactive immune system. And they look at various biomarkers that are on the market to assess that. As part of that workup, we understand that those clinicians are using a serology test to confirm whether or not those individuals have had prior exposure to SARS-CoV-2 and developed an antibody response. So that can be very helpful in the assessment of those kids. And, certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response. Hopefully, that addresses your question.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-COVID syndrome diagnostics, Serology testing, FDA evaluation process
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Are there specific biomarkers or serology tests identified by the FDA to confirm prior exposure to SARS-CoV-2 for long COVID cases?
CLARIFIED ANSWER: The FDA recognizes that serology tests can confirm prior SARS-CoV-2 exposure and that clinicians use biomarkers to assess symptoms of long COVID. While the FDA reviews testing technologies for their potential benefits, standard recommendations for such tests do not yet exist.
VERBATIM QUESTION: Are there specific biomarkers or serology tests identified by the FDA to confirm prior exposure to SARS-CoV-2 for long COVID cases?
VERBATIM ANSWER: So we know that at least some of these cases did not have an original documented diagnostic test confirmation of COVID with, say, an antigen test or an RT-PCR test. And so clinicians are seeing symptoms of an overactive immune system. And they look at various biomarkers that are on the market to assess that. As part of that workup, we understand that those clinicians are using a serology test to confirm whether or not those individuals have had prior exposure to SARS-CoV-2 and developed an antibody response. So that can be very helpful in the assessment of those kids. And, certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Long COVID diagnostics, Serology tests, Biomarkers
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: Is the FDA open to evaluating new tests or technologies for assessing long COVID?
CLARIFIED ANSWER: The FDA is open to evaluating new tests or technologies for assessing long COVID. While no standardized approach exists due to varied technology proposals, they assess applications on a case-by-case basis for their benefit and risk.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So we know that at least some of these cases did not have an original documented diagnostic test confirmation of COVID with, say, an antigen test or an RT-PCR test. And so clinicians are seeing symptoms of an overactive immune system. And they look at various biomarkers that are on the market to assess that. As part of that workup, we understand that those clinicians are using a serology test to confirm whether or not those individuals have had prior exposure to SARS-CoV-2 and developed an antibody response. So that can be very helpful in the assessment of those kids. And, certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response. Hopefully, that addresses your question.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Long COVID diagnostics, Test development, FDA evaluation process
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: What are the FDA's expectations for labeling instructions on over-the-counter COVID-19 test kits to minimize misuse?
CLARIFIED ANSWER: FDA expects over-the-counter COVID-19 test labeling to provide clear instructions for serial testing but recognizes the challenges since there are no resources to enforce adherence. FDA considers these risks carefully when evaluating emergency use authorizations.
VERBATIM QUESTION: What are the FDA's expectations for labeling instructions on over-the-counter COVID-19 test kits to minimize misuse?
VERBATIM ANSWER: Ah, OK, yes, two questions. So, unfortunately or maybe fortunately, we don't have the resources to check that home OTC users are doing serial testing. That's how the devices are labeled, and that's how we want them to test. But there's really-- we don't expect the manufacturers to ensure that their users are following that. What we expect is that the labeling is good, instructs them on what to do, and then we understand that, when things go to an OTC environment, that they could be used in all sorts of different ways. And that is a risk of OTC when a clinician is not involved. And it's why really the FDA is a lot more cautious in authorizing OTCs. Now, obviously, we've done it numerous times, but those are the-- when we do our likely benefit to likely risk calculations for every EUA, for OTC, that goes into the hopper. And we compute that at least with brain power.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC test labeling, FDA expectations, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: How does the FDA assess the risk versus benefit for authorizing over-the-counter COVID-19 tests during the EUA process?
CLARIFIED ANSWER: The FDA considers the risks, such as improper use without clinician oversight, and the benefits when authorizing over-the-counter COVID-19 tests, ensuring labeling instructions are clear and assessing each case carefully.
VERBATIM QUESTION: How does the FDA assess the risk versus benefit for authorizing over-the-counter COVID-19 tests during the EUA process?
VERBATIM ANSWER: That's how the devices are labeled, and that's how we want them to test. But there's really-- we don't expect the manufacturers to ensure that their users are following that. What we expect is that the labeling is good, instructs them on what to do, and then we understand that, when things go to an OTC environment, that they could be used in all sorts of different ways. And that is a risk of OTC when a clinician is not involved. And it's why really the FDA is a lot more cautious in authorizing OTCs. Now, obviously, we've done it numerous times, but those are the-- when we do our likely benefit to likely risk calculations for every EUA, for OTC, that goes into the hopper. And we compute that at least with brain power.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Risk-benefit assessment, EUA process, Over-the-counter tests
REVIEW FLAG: False

QA Block 13-8
CLARIFIED QUESTION: Are developers expected to monitor how users perform serial testing for over-the-counter COVID-19 diagnostics?
CLARIFIED ANSWER: Developers are not expected to monitor if users perform serial testing for over-the-counter diagnostics. The FDA requires proper labeling and understands that OTC products carry a risk of misuse without clinician involvement.
VERBATIM QUESTION: Are developers expected to monitor how users perform serial testing for over-the-counter COVID-19 diagnostics?
VERBATIM ANSWER: So, unfortunately or maybe fortunately, we don't have the resources to check that home OTC users are doing serial testing. That's how the devices are labeled, and that's how we want them to test. But there's really-- we don't expect the manufacturers to ensure that their users are following that. What we expect is that the labeling is good, instructs them on what to do, and then we understand that, when things go to an OTC environment, that they could be used in all sorts of different ways. And that is a risk of OTC when a clinician is not involved. And it's why really the FDA is a lot more cautious in authorizing OTCs. Now, obviously, we've done it numerous times, but those are the-- when we do our likely benefit to likely risk calculations for every EUA, for OTC, that goes into the hopper. And we compute that at least with brain power.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serial testing monitoring, OTC diagnostics labeling
REVIEW FLAG: False

QA Block 13-9
CLARIFIED QUESTION: What are the FDA's considerations for evaluating new types of tests or biomarkers for long COVID in children and other populations?
CLARIFIED ANSWER: The FDA is examining biomarkers and serology tests used by clinicians to evaluate long COVID in children and other populations. They assess new test applications individually due to the varying technologies involved and are open to evaluating those that may help in the pandemic response.
VERBATIM QUESTION: What are the FDA's considerations for evaluating new types of tests or biomarkers for long COVID in children and other populations?
VERBATIM ANSWER: So we know that at least some of these cases did not have an original documented diagnostic test confirmation of COVID with, say, an antigen test or an RT-PCR test. And so clinicians are seeing symptoms of an overactive immune system. And they look at various biomarkers that are on the market to assess that. As part of that workup, we understand that those clinicians are using a serology test to confirm whether or not those individuals have had prior exposure to SARS-CoV-2 and developed an antibody response. So that can be very helpful in the assessment of those kids. And, certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Long COVID diagnostics, Biomarkers and serology tests, FDA evaluation process
REVIEW FLAG: False

QA Block 13-10
CLARIFIED QUESTION: What type of information should test developers provide when submitting applications for novel long COVID diagnostic technologies?
CLARIFIED ANSWER: The FDA assesses novel long COVID diagnostic applications case-by-case due to technology variability. Developers should propose ideas showing benefit in the pandemic response, though no standardized recommendations exist.
VERBATIM QUESTION: What type of information should test developers provide when submitting applications for novel long COVID diagnostic technologies?
VERBATIM ANSWER: Certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: long COVID diagnostics, novel diagnostic applications, FDA review process
REVIEW FLAG: False

QA Block 13-11
CLARIFIED QUESTION: Are there any standard guidelines for developing non-traditional tests for long COVID, or is each proposal assessed individually?
CLARIFIED ANSWER: The FDA currently assesses each proposal for non-traditional long COVID tests individually, as the technologies and ideas vary widely. It is challenging to establish standard guidelines due to the diverse approaches involved.
VERBATIM QUESTION: Are there any standard guidelines for developing non-traditional tests for long COVID, or is each proposal assessed individually?
VERBATIM ANSWER: So we know that at least some of these cases did not have an original documented diagnostic test confirmation of COVID with, say, an antigen test or an RT-PCR test. And so clinicians are seeing symptoms of an overactive immune system. And they look at various biomarkers that are on the market to assess that. As part of that workup, we understand that those clinicians are using a serology test to confirm whether or not those individuals have had prior exposure to SARS-CoV-2 and developed an antibody response. So that can be very helpful in the assessment of those kids. And, certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Development of long COVID diagnostics, FDA regulatory process, Assessment of non-traditional tests
REVIEW FLAG: False


#### 14. FDA Comparator Requirements for Respiratory Panel Development

QA Block 14-1
CLARIFIED QUESTION: For developers seeking approval for a respiratory panel molecular test, is the BioFire Respiratory Panel 2.1 the only comparator device required by the FDA?
CLARIFIED ANSWER: The BioFire Respiratory Panel 2.1 is the formal predicate device for 510K pathway tests but is not the only required comparator. Developers can use other EUA-authorized tests as comparators if BioFire is unavailable.
VERBATIM QUESTION: For developers seeking approval for a respiratory panel molecular test, is the BioFire Respiratory Panel 2.1 the only comparator device required by the FDA?
VERBATIM ANSWER: Yeah, for the 510K pathway follow-on molecular assays that can follow that reg, the BioFire assay is the formal predicate device. That does not mean that it has to be the comparator. And Toby, I know you're a little bit more fluent in this. And maybe I can have you finish our response. Sure. Yeah, so we have discussed this on this call previously, although it would probably be several weeks back if you wanted to go look at the transcript. But yeah, we have talked about this that BioFire is the formal predicate, as it is the only test that is legally marketed beyond an EUA. But you can still use other EUA-authorized tests as your comparator since we know that BioFire may not be available to all developers as a comparator.
SPEAKER QUESTION: Sean Gregory
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Respiratory panel tests, 510K pathway, Comparators for test approval
REVIEW FLAG: False


#### 15. Serology Testing and Viral Load in Long-Haulers

QA Block 15-1
CLARIFIED QUESTION: Is there a viral load serology test being developed for people with long-term symptoms or to help lower the viral load for long-haulers?
CLARIFIED ANSWER: FDA notes that the level of antibodies may not correspond directly to the viral load in patients. However, there are developers working on blood-based virus detection tests; if the supporting data is adequate, FDA may authorize it.
VERBATIM QUESTION: Is there a viral load serology test being developed for people with long-term symptoms or to help lower the viral load for long-haulers?
VERBATIM ANSWER: Regarding a viral load, the level of antibodies, we don't know if it corresponds to the viral loads that we're seeing in the patient versus maybe more patient-specific immune responses. But I'm not sure exactly what your question is. But we also know that there are developers out there who are working on blood-based detection of the virus, viral infection. So it's obviously a non-standard sample type, but we will look at the data. And, if the data supports the use of a blood-based detection of virus, then we may be able to authorize that.
SPEAKER QUESTION: Username FFIM2601
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: viral load serology tests, long-haulers, blood-based detection
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Can serology differentiate between natural infection and vaccination, such as through neutralization antibodies versus spike protein antibodies?
CLARIFIED ANSWER: Clinicians can use serology tests to determine if antibodies indicate vaccination (spike protein-only antibodies) or natural infection (antibodies to other virus parts like N protein). A positive spike protein and negative N protein signal vaccination, while both being positive suggests natural infection possibly combined with vaccination.
VERBATIM QUESTION: Can serology differentiate between natural infection and vaccination, such as through neutralization antibodies versus spike protein antibodies?
VERBATIM ANSWER: Yes, we put out some communication. Toby can correct me here. So clinicians can definitely use the appropriate serology test or tests to assess whether just spike protein antibodies have been formed versus some other part of the virus that other assays, but the vaccines don't target. So, obviously, positive on spike protein and negative on, say, N protein would suggest vaccination only. But, if you were to also see and confirm N protein antibodies as well, then it would suggest that there had been a natural infection plus or minus vaccine.
SPEAKER QUESTION: Username FFIM2601
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, Natural infection vs. vaccination, Neutralization antibodies
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: Can clinicians use serology tests to distinguish between different viral proteins not targeted by vaccines?
CLARIFIED ANSWER: Clinicians can use serology tests to determine if spike protein antibodies, associated with vaccination, are present or if N protein antibodies indicate natural infection, with or without vaccination.
VERBATIM QUESTION: Can clinicians use serology tests to distinguish between different viral proteins not targeted by vaccines?
VERBATIM ANSWER: Yes, we put out some communication. Toby can correct me here. So clinicians can definitely use the appropriate serology test or tests to assess whether just spike protein antibodies have been formed versus some other part of the virus that other assays, but the vaccines don't target. So, obviously, positive on spike protein and negative on, say, N protein would suggest vaccination only. But, if you were to also see and confirm N protein antibodies as well, then it would suggest that there had been a natural infection plus or minus vaccine.
SPEAKER QUESTION: Username FFIM2601
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, Vaccine response, Natural infection
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: Does the level of antibodies in blood correlate directly with viral load?
CLARIFIED ANSWER: The FDA states that it is unclear whether antibody levels in the blood correlate directly with viral load, as this might depend on individual immune responses.
VERBATIM QUESTION: Does the level of antibodies in blood correlate directly with viral load?
VERBATIM ANSWER: Regarding a viral load, the level of antibodies, we don't know if it corresponds to the viral loads that we're seeing in the patient versus maybe more patient-specific immune responses.
SPEAKER QUESTION: Username FFIM2601
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antibody levels and viral load, immune response
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: What data requirements must developers meet to gain FDA authorization for blood-based virus detection?
CLARIFIED ANSWER: FDA may authorize blood-based virus detection if submitted data supports its safety and effectiveness, even though it is a non-standard sample type.
VERBATIM QUESTION: What data requirements must developers meet to gain FDA authorization for blood-based virus detection?
VERBATIM ANSWER: Regarding a viral load, the level of antibodies, we don't know if it corresponds to the viral loads that we're seeing in the patient versus maybe more patient-specific immune responses. But I'm not sure exactly what your question is. But we also know that there are developers out there who are working on blood-based detection of the virus, viral infection. So it's obviously a non-standard sample type, but we will look at the data. And, if the data supports the use of a blood-based detection of virus, then we may be able to authorize that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: blood-based virus detection, FDA data review, diagnostic authorization
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: What are the key updates or changes in the accessibility of presentations and transcripts on CDRH Learn?
CLARIFIED ANSWER: The FDA has updated the title of the CDRH Learn subsection to make navigation easier. Presentations and transcripts from this town hall will be available within a week under the subsection 'Coronavirus, COVID-19, Test Development and Validation Virtual Town Hall Series.'
VERBATIM QUESTION: What are the key updates or changes in the accessibility of presentations and transcripts on CDRH Learn?
VERBATIM ANSWER: Today's presentation and transcript will be available at CDRH Learn in about a week. You can visit CDRH Learn at www.fda.gov/Training/CDRHLearn. Note that we've updated the title of this section to make it easier to navigate. You'll now find the recordings in the subsection titled Coronavirus, COVID-19, Test Development and Validation Virtual Town Hall Series.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Anike Freeman (FDA)
TOPICS: CDRH Learn updates, Presentation transcripts
REVIEW FLAG: False

QA Block 15-7
CLARIFIED QUESTION: What are the guidelines for providing feedback about the virtual town hall program?
CLARIFIED ANSWER: Feedback about the virtual town hall program can be provided by completing a brief survey at www.fda.gov/CDRHWebinar.
VERBATIM QUESTION: What are the guidelines for providing feedback about the virtual town hall program?
VERBATIM ANSWER: As we continue to hold these virtual town halls, we appreciate your feedback about the program. Please complete a brief survey, which you may find at www.fda.gov/CDRHWebinar.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Anike Freeman (FDA)
TOPICS: feedback guidelines, virtual town hall program
REVIEW FLAG: False

### removed qa blocks
QA Block 2-3
CLARIFIED QUESTION: Do we need to submit an EUA if a test is performed in a CLIA lab?
CLARIFIED ANSWER: EUA submission requirements for tests performed solely within a single CLIA lab without home collection are still under discussion with HHS.
VERBATIM QUESTION: Do we need to submit an EUA if a test is performed in a CLIA lab?
VERBATIM ANSWER: If it is a test that is developed and used solely in a single lab-- so it's a lab-developed test that does not have home collection-- then that is something that is still under discussion with HHS regarding the statement they issued last summer about LDTs.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA lab testing, EUA requirements, LDT discussions
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Do we need to submit an EUA if a test is performed in a CLIA lab and involves home collection?
CLARIFIED ANSWER: Home collection is considered a device and requires FDA review. An EUA submission is needed for adding home collection to an LDT.
VERBATIM QUESTION: Do we need to submit an EUA if a test is performed in a CLIA lab and involves home collection?
VERBATIM ANSWER: Yeah, so home collection is considered a device. And we do require review of that. And so, if you have an LDT that wants to add home collection, then we look forward to getting the submission and working with you.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirement, home collection tests, LDTs
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Do we need to submit an EUA if a test is performed in a CLIA lab and involves collection from clinics?
CLARIFIED ANSWER: FDA expects you to submit an EUA if the test is performed in a CLIA lab and involves collection from clinics.
VERBATIM QUESTION: Do we need to submit an EUA if a test is performed in a CLIA lab and involves collection from clinics?
VERBATIM ANSWER: Right, so, for that, we would expect to see an EUA request for that.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements, CLIA lab testing, clinical collection
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Is this a single CLIA lab developing a lab-developed test (LDT), and does it require an EUA?
CLARIFIED ANSWER: If it is a single CLIA lab developing an LDT without home collection, it is under discussion with HHS. Otherwise, an EUA is required.
VERBATIM QUESTION: Is this a single CLIA lab developing a lab-developed test (LDT), and does it require an EUA?
VERBATIM ANSWER: OK, so then it is-- it would need an EUA. Yeah, if it is a-- if it is a test that is developed and used solely in a single lab-- so it's a lab-developed test that does not have home collection-- then that is something that is still under discussion with HHS regarding the statement they issued last summer about LDTs.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: LDT requirements, CLIA lab, EUA necessity
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: Does a test kit sent to the CLIA lab from either point of care or home require an EUA?
CLARIFIED ANSWER: A test kit sent to a CLIA lab from point of care or home requires an EUA unless it is a lab-developed test used solely in a single lab without home collection. Such cases are still under discussion with HHS.
VERBATIM QUESTION: Does a test kit sent to the CLIA lab from either point of care or home require an EUA?
VERBATIM ANSWER: OK, so then it is-- it would need an EUA. Yeah, if it is a-- if it is a test that is developed and used solely in a single lab-- so it's a lab-developed test that does not have home collection-- then that is something that is still under discussion with HHS regarding the statement they issued last summer about LDTs.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirement, CLIA lab testing, Lab-developed tests
REVIEW FLAG: False

QA Block 2-12
CLARIFIED QUESTION: When does use of a test kit in a CLIA lab require an EUA submission?
CLARIFIED ANSWER: A test kit used in a CLIA lab would need an EUA. A lab-developed test used solely in a single lab without home collection is under discussion with HHS.
VERBATIM QUESTION: When does use of a test kit in a CLIA lab require an EUA submission?
VERBATIM ANSWER: OK, so then it is-- it would need an EUA. Yeah, if it is a-- if it is a test that is developed and used solely in a single lab-- so it's a lab-developed test that does not have home collection-- then that is something that is still under discussion with HHS regarding the statement they issued last summer about LDTs.
SPEAKER QUESTION: John Mann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA labs, EUA requirements, home collection
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What does it mean for a test to be interpreted using a smartphone app?
CLARIFIED ANSWER: A test interpreted using a smartphone app involves the camera capturing an image, using image analysis to determine if the test is positive or negative. Manually recording results on the smartphone does not constitute interpretation by the app.
VERBATIM QUESTION: What does it mean for a test to be interpreted using a smartphone app?
VERBATIM ANSWER: Yeah. So, when we talk about a smartphone app interpreting the test, it's not recording. It's not having the patient record the result on the smartphone manually. It's you have a camera function. And you have a camera function, and the camera records an image. And it is image analysis, and the smartphone image analysis is deciding whether the test is positive or negative. It's when the smartphone is doing all of that that we need to see a separate 30 positive and 30 negative in the OTC environment. But, if all of the smartphone is doing is having the patient record the result that they visually read, that is part of the user testing and the clinical study. And you don't need to have a separate study to analyze that.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone app interpretation, COVID-19 test analysis
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Is manually entering visually read test results into a smartphone app considered interpretation by the smartphone app?
CLARIFIED ANSWER: Manually entering visually read test results into a smartphone app is not considered interpretation by the app. Interpretation involves using the smartphone's camera to capture an image and analyze it automatically.
VERBATIM QUESTION: Is manually entering visually read test results into a smartphone app considered interpretation by the smartphone app?
VERBATIM ANSWER: Yeah. So, when we talk about a smartphone app interpreting the test, it's not recording. It's not having the patient record the result on the smartphone manually. It's you have a camera function. And you have a camera function, and the camera records an image. And it is image analysis, and the smartphone image analysis is deciding whether the test is positive or negative. It's when the smartphone is doing all of that that we need to see a separate 30 positive and 30 negative in the OTC environment. But, if all of the smartphone is doing is having the patient record the result that they visually read, that is part of the user testing and the clinical study. And you don't need to have a separate study to analyze that.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone app interpretation, Clinical study requirements
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: What does the FDA consider 'conditions of use' for a home collection device?
CLARIFIED ANSWER: The FDA considers 'conditions of use' for a home collection device to include whether it has been authorized for specific purposes or received an EUA for such use, requiring explanation of its usage if not meeting these conditions.
VERBATIM QUESTION: What does the FDA consider 'conditions of use' for a home collection device?
VERBATIM ANSWER: Typically, all home collections, for something that hasn't already been FDA authorized for that specific purpose or hasn't already received an EUA for that specific purpose and you're just using it within all the conditions of the use of that home collection device, we're going to want you to come in and explain what you're doing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection devices, conditions of use, FDA review
REVIEW FLAG: False

QA Block 12-1
CLARIFIED QUESTION: Is it necessary to update the EUA for all app changes of the product already granted EUA?
CLARIFIED ANSWER: If the changes do not affect performance, sensitivity, specificity, or usability, an EUA update is unlikely to be required. FDA recommends clarifying requirements with the review team during the initial review process.
VERBATIM QUESTION: Is it necessary to update the EUA for all app changes of the product already granted EUA?
VERBATIM ANSWER: Yeah, so, if it doesn't affect the performance, the sensitivity, specificity, usability of the test, then we're unlikely to ask for any data. But I would bring that up in the initial review process of your test and address that question with our front-line review staff. And they can give you a more detailed response on when they would like to see an amendment or supplement and when they don't need to see it or when they just want to get a notification or something, OK?
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA updates, app changes, FDA review process
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Is the FDA doing anything related to the post-COVID-19 syndrome?
CLARIFIED ANSWER: FDA acknowledges that many post-COVID cases lack documented diagnostic confirmation. Clinicians use serology tests to identify prior exposure, and FDA actively evaluates potential tests to diagnose and monitor long COVID, though recommendations vary by technology.
VERBATIM QUESTION: Is the FDA doing anything related to the post-COVID-19 syndrome?
VERBATIM ANSWER: So we know that at least some of these cases did not have an original documented diagnostic test confirmation of COVID with, say, an antigen test or an RT-PCR test. And so clinicians are seeing symptoms of an overactive immune system. And they look at various biomarkers that are on the market to assess that. As part of that workup, we understand that those clinicians are using a serology test to confirm whether or not those individuals have had prior exposure to SARS-CoV-2 and developed an antibody response. So that can be very helpful in the assessment of those kids. And, certainly, there is interest in developers. And we've had ongoing conversations about additional tests that may help assess whether or not it is long COVID in kids or in others or not. And so the FDA is committed to taking a look at those ideas and those applications and assessing them for their benefit/risk in this pandemic response. So they really-- it's not something that we can easily come up with a template and a set of recommendations for because these technologies really are all over the map in ideas. And so it's not something like, we know what the virus is, and we're going to detect it with molecular means, antigen means, or serology means. Those are a lot more standard sort of ways to assess infection or prior infection. And so we take these one off. We assess them one by one. And, certainly, as I said, we would be open to assessing these technologies for their benefit in the pandemic response. Hopefully, that addresses your question.
SPEAKER QUESTION: Raouf Guirguis
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-COVID syndrome, diagnostics development, FDA evaluation
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Are two additional EUA-approved or FDA-approved devices still required as comparators for a respiratory panel molecular test?
CLARIFIED ANSWER: BioFire Respiratory Panel 2.1 is the formal predicate device for 510K pathway assays but does not have to be the comparator. Other EUA-authorized tests may be used if BioFire is not available.
VERBATIM QUESTION: Are two additional EUA-approved or FDA-approved devices still required as comparators for a respiratory panel molecular test?
VERBATIM ANSWER: Yeah, for the 510K pathway follow-on molecular assays that can follow that reg, the BioFire assay is the formal predicate device. That does not mean that it has to be the comparator. And Toby, I know you're a little bit more fluent in this. And maybe I can have you finish our response. Sure. Yeah, so we have discussed this on this call previously, although it would probably be several weeks back if you wanted to go look at the transcript. But yeah, we have talked about this that BioFire is the formal predicate, as it is the only test that is legally marketed beyond an EUA. But you can still use other EUA-authorized tests as your comparator since we know that BioFire may not be available to all developers as a comparator.
SPEAKER QUESTION: Sean Gregory
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA-approved comparator devices, Respiratory panel molecular tests
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-04 08:20:42 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 15
##### Explicit Questions Extraction
QE 1-1: What review pathway does the FDA recommend for an antigen test for SARS-CoV-2, either the EUA review pathway or the traditional premarket review pathway?
QE 1-2: What additional clinical performance requirements are there for traditional premarket review pathways, such as 510K or de novo, compared to an EUA request?
QE 1-3: Are both prospective and retrospective studies required if a developer plans to use the traditional premarket review pathway for an antigen test for SARS-CoV-2?

##### Implicit Questions Extraction
QI 1-1: What types of diagnostic tests are considered high-priority by the FDA in the current stage of the pandemic?
QI 1-2: Why are prescription multianalyte tests prioritized, but not over-the-counter multianalyte tests?
QI 1-3: Does the FDA provide written responses for case-specific questions not addressed during the town hall?
QI 1-4: What steps should developers take if they do not receive a written response from the FDA within a few days after submitting a question?
QI 1-5: What lessons can be learned from the decision summary for the SARS-CoV-2 BioFire de novo to guide full marketing authorization submissions for other tests?

#### Section 2 of 15
##### Explicit Questions Extraction
QE 2-1: Are you still accepting CLIA lab-based EUA applications?
QE 2-2: What would be the expected turnaround or response time for CLIA lab-based EUA applications?
QE 2-3: Do we need to submit an EUA if a test is performed in a CLIA lab?
QE 2-4: Do we need to submit an EUA if a test is performed in a CLIA lab and involves home collection?
QE 2-5: Do we need to submit an EUA if a test is performed in a CLIA lab and involves collection from clinics?
QE 2-6: Is this a single CLIA lab developing a lab-developed test (LDT), and does it require an EUA?
QE 2-7: Does a test kit sent to the CLIA lab from either point of care or home require an EUA?
QE 2-8: For a developer creating a test performed solely in a CLIA lab at point of care, would an EUA request be required?

##### Implicit Questions Extraction
QI 2-1: What constitutes a home collection device requiring FDA review?
QI 2-2: Under what circumstances does an LDT need to submit an EUA for adding home collection?
QI 2-3: Are LDTs without home collection devices still under regulatory discussion with HHS?
QI 2-4: When does use of a test kit in a CLIA lab require an EUA submission?
QI 2-5: What steps should a developer follow to clarify specific test scenarios with the FDA?

#### Section 3 of 15
##### Explicit Questions Extraction
QE 3-1: Does the inclusion of both vaccinated and unvaccinated individuals change the sample size considerations for a total antibody test clinical trial?
QE 3-2: Does the FDA have a recommendation on the distribution of positive and negative samples required if both vaccinated and unvaccinated individuals are included?

##### Implicit Questions Extraction
QI 3-1: What challenges do vaccinated individuals present when being used as positives in total antibody tests?
QI 3-2: Can pre-pandemic banked negative samples be used to meet negative sample requirements?
QI 3-3: What should test developers do if they face difficulties obtaining true negative samples due to vaccination and infection rates?
QI 3-4: When would the FDA consider moving to a different comparator method for test validation?
QI 3-5: Are there any guidelines on the use of seroprevalence data to estimate sample availability?

#### Section 4 of 15
##### Explicit Questions Extraction
QE 4-1: Do a certain number of positives and negatives need to come specifically from participants using paper instructions versus a smartphone app for clinical evaluation of OTC home-use antigen tests?
QE 4-2: What does it mean for a test to be interpreted using a smartphone app?
QE 4-3: Is manually entering visually read test results into a smartphone app considered interpretation by the smartphone app?
QE 4-4: Does interpreting a test with a smartphone app require the device to capture and analyze an image to determine results?

##### Implicit Questions Extraction
QI 4-1: What is the difference between a smartphone app capturing and analyzing an image versus a user manually recording the result?
QI 4-2: For tests interpreted entirely by smartphone image analysis, what validation data does the FDA require?
QI 4-3: If a smartphone app is only used to record a manually read result, does this require a separate clinical evaluation?

#### Section 5 of 15
##### Explicit Questions Extraction
QE 5-1: What happens for a blood spot collected in the home setting and sent through the mail?
QE 5-2: If a blood spot collected in the home setting can be validated for sensitivity and specificity, can the lab director sign off on a sample collected in that way?

##### Implicit Questions Extraction

#### Section 6 of 15
##### Explicit Questions Extraction
QE 6-1: For a saliva COVID test intended for the CLIA setting with freshly collected saliva, would it be acceptable to use artificial saliva or another commercial source of saliva where the saliva isn't fresh?
QE 6-2: Do we have to use freshly collected saliva for determining the LoD for a saliva COVID test?
QE 6-3: Can I send an email to ask a specific question regarding use of artificial or frozen samples?

##### Implicit Questions Extraction
QI 6-1: What are the challenges in using saliva as a sample type in COVID-19 diagnostics?
QI 6-2: Are fresh/frozen sample comparison studies required when using frozen banked saliva for validation?
QI 6-3: How should developers frame their questions about assay validation when contacting the FDA review staff?
QI 6-4: Is it necessary to submit questions about saliva sample validation in the context of a pre-EUA submission?
QI 6-5: When could freezing a saliva sample artificially increase test sensitivity?

#### Section 7 of 15
##### Explicit Questions Extraction
QE 7-1: If we update our mobile app to help school reopening, how much will it slow down our EUA review process?

##### Implicit Questions Extraction
QI 7-1: How does the FDA determine whether an app change will require restarting the review process?
QI 7-2: What details about the changes to a mobile app should developers include when contacting the FDA for feedback?
QI 7-3: Is there a specific point of contact or address to submit queries regarding updates to mobile applications tied to COVID-19 diagnostic tests?

#### Section 8 of 15
##### Explicit Questions Extraction
QE 8-1: Would a home collection kit for a nasal swab specimen qualify as part of the LDT, which is a PCR test, or would it require an EUA?

##### Implicit Questions Extraction
QI 8-1: What are the FDA's expectations for explaining the intended use of unauthorized home collection devices?
QI 8-2: Are there any specific conditions under which home collection devices might bypass the EUA process?
QI 8-3: Does the FDA classify all home collection kits as devices subject to review, even if they are not commercially sold?
QI 8-4: What does the FDA consider 'conditions of use' for a home collection device?

#### Section 9 of 15
##### Explicit Questions Extraction
QE 9-1: What is the FDA's view on the importance and priority of antibody testing and immunity assessment in light of recent CDC data on vaccine efficacy?
QE 9-2: Does the eight-month booster recommendation apply uniformly across individuals, and could serology tests help determine personal immunity status?

##### Implicit Questions Extraction
QI 9-1: What criteria will the FDA use to define a fully quantitative COVID-19 serology test?
QI 9-2: Are there plans to establish an international standard for SARS-CoV-2 antibody levels similar to rubella?
QI 9-3: If an existing authorized serology test meets a future international standard, will the FDA update its authorization automatically without requiring new outcome studies?
QI 9-4: How does the presence of COVID-19 variants like Delta impact the ability to define universal immunity thresholds through serology testing?
QI 9-5: Would population-level serology studies using p-values be insufficient for creating clinical recommendations tailored to individual patients?
QI 9-6: What safeguards are in place to prevent the misuse of serology tests in making personalized clinical decisions?
QI 9-7: Under what specific circumstances might the FDA consider supporting immunity claims for serology tests?
QI 9-8: How does the complexity of interpreting antibody responses influence FDA guidelines or recommendations for serology use?

#### Section 10 of 15
##### Explicit Questions Extraction
QE 10-1: Would you be utilizing the RT-PCR to screen and enroll for the serology clinical testing people who are positive at their initial visit?
QE 10-2: When conducting serology testing, would you have patients undergo nasal samplings at day 7, day 14, or day 15 after their initial test if they do a follow-on visit?
QE 10-3: Are you asking patients to do both a blood test and a nasal swab for serology clinical testing?

##### Implicit Questions Extraction

#### Section 11 of 15
##### Explicit Questions Extraction
QE 11-1: Does the FDA have any general limitations, considerations, or recommendations on selecting a cleared flu method to serve as a comparator for a multianalyte antigen test?

##### Implicit Questions Extraction

#### Section 12 of 15
##### Explicit Questions Extraction
QE 12-1: Is it necessary to update the EUA for all app changes of the product already granted EUA?
QE 12-2: Is it necessary to update the EUA for app changes that do not involve the operation and use of the kit and do not affect safety and effectiveness?

##### Implicit Questions Extraction
QI 12-1: What factors determine whether the FDA requires additional data for app updates that impact test performance, sensitivity, specificity, or usability?
QI 12-2: Can test developers address the need for EUA amendments or notifications during the initial review process?
QI 12-3: Are there defined guidelines for when the FDA requires notifications, amendments, or supplements for app updates?

#### Section 13 of 15
##### Explicit Questions Extraction
QE 13-1: How is the FDA policing the serial testing to prevent people from misinterpreting usage instructions and reporting positives incorrectly?
QE 13-2: Is the FDA doing anything related to the post-COVID-19 syndrome?
QE 13-3: Is the FDA assisting clinicians in diagnosing or monitoring post-COVID syndrome cases?
QE 13-4: Are there specific biomarkers or serology tests identified by the FDA to confirm prior exposure to SARS-CoV-2 for long COVID cases?
QE 13-5: Is the FDA open to evaluating new tests or technologies for assessing long COVID?

##### Implicit Questions Extraction
QI 13-1: What are the FDA's expectations for labeling instructions on over-the-counter COVID-19 test kits to minimize misuse?
QI 13-2: How does the FDA assess the risk versus benefit for authorizing over-the-counter COVID-19 tests during the EUA process?
QI 13-3: Are developers expected to monitor how users perform serial testing for over-the-counter COVID-19 diagnostics?
QI 13-4: What are the FDA's considerations for evaluating new types of tests or biomarkers for long COVID in children and other populations?
QI 13-5: What type of information should test developers provide when submitting applications for novel long COVID diagnostic technologies?
QI 13-6: Are there any standard guidelines for developing non-traditional tests for long COVID, or is each proposal assessed individually?

#### Section 14 of 15
##### Explicit Questions Extraction
QE 14-1: For developers seeking approval for a respiratory panel molecular test, is the BioFire Respiratory Panel 2.1 the only comparator device required by the FDA?
QE 14-2: Are two additional EUA-approved or FDA-approved devices still required as comparators for a respiratory panel molecular test?

##### Implicit Questions Extraction

#### Section 15 of 15
##### Explicit Questions Extraction
QE 15-1: Is there a viral load serology test being developed for people with long-term symptoms or to help lower the viral load for long-haulers?
QE 15-2: Can serology differentiate between natural infection and vaccination, such as through neutralization antibodies versus spike protein antibodies?

##### Implicit Questions Extraction
QI 15-1: Can clinicians use serology tests to distinguish between different viral proteins not targeted by vaccines?
QI 15-2: Does the level of antibodies in blood correlate directly with viral load?
QI 15-3: What data requirements must developers meet to gain FDA authorization for blood-based virus detection?
QI 15-4: What are the key updates or changes in the accessibility of presentations and transcripts on CDRH Learn?
QI 15-5: What are the guidelines for providing feedback about the virtual town hall program?
